Is there actually a proven benefit of intensive blood glucose control in patients who have diabetes, and if there is what actually is that benefit? In this 8-minute podcast, Drs. Jack Leahy and Doron Schneider answer this question based on data from The Diabetes Control and Complications study.
The results of the Diabetes Control and Complications Trial (DCCT) showed an outstanding benefit of almost 70 percent reduction in microvascular disease when driving down A1C to 7, but also showed a higher frequency of hypoglycemia -- events that patients don’t forget. "It was clear intensive therapy back then came with a significant price."
Doron Schneider, MD and Jack Leahy, MD discuss the pros and cons of bariatric surgery as an initial treatment option.
Doron Schneider, MD and Jack Leahy, MD discuss the importance of patient BMI and other risk factors for coronary artery disease when weighing treatment options.
Listen to the podcast or read the transcript
Dr. Jack Leahy, endocrinologist and general internist, Dr. Doron Schneider, weigh different initial treatment options presented by leading endocrinologists Silvio Inzucchi, MD, Alan J. Garber, MD and Laurence Kennedy, MD
In the past decade or so, our attempts to define the "earliest” events in Type 2 diabetes (T2DM) have moved increasingly earlier. We’re considering even the years before what we now consider to be the “pre-diabetes” stage—that is, years considerably before there are any clinical signs or symptoms of disease.
